Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00448864
Status:
TERMINATED
Last Update Posted:
2019-06-25
First Post:
2007-03-16
Brief Title:
Efficacy Study of Recombinant Protein Ecallantide to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve RepairReplacement
Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization Data
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Class:
INDUSTRY
Study ID:
1501-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None